What's in Xiaobo Yang, MD's pipeline?

Xiaobo Yang, MD has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Xiaobo Yang, MD's portfolio?

Top competitors by shared drug class: Alkermes, Inc., Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Universitaire de Saint Etienne, The Cleveland Clinic, University Hospital, Clermont-Ferrand.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xiaobo-yang-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Xiaobo Yang, MD — Portfolio Competitive Intelligence Brief

Xiaobo Yang, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Anesthesiology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alkermes, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Centre Hospitalier Universitaire de Saint Etienne · 1 shared drug class
The Cleveland Clinic · 1 shared drug class
University Hospital, Clermont-Ferrand · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xiaobo Yang, MD:

Cite this brief

Drug Landscape (2026). Xiaobo Yang, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xiaobo-yang-md. Accessed 2026-05-14.